Cargando…
Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
BACKGROUND: 14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ expression in patie...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222637/ https://www.ncbi.nlm.nih.gov/pubmed/18036248 http://dx.doi.org/10.1186/1471-2407-7-217 |
_version_ | 1782149361697816576 |
---|---|
author | Motokura, Toru Nakamura, Yukari Sato, Hiroyuki |
author_facet | Motokura, Toru Nakamura, Yukari Sato, Hiroyuki |
author_sort | Motokura, Toru |
collection | PubMed |
description | BACKGROUND: 14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ expression in patients with haematological malignancies. METHODS: We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3σ expression with real-time RT-PCR. We also examined protein levels by Western blot analysis and DNA methylation status of the 14-3-3σ gene by methylation-specific PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-PCR-SSCP analysis and the expression levels of 14-3-3σ were compared with those of other cell-cycle inhibitor genes, CDKN2A and ARF. RESULTS: The expression levels of 14-3-3σ mRNA in almost all cell lines were low and comparable to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3σ mRNA was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and rarely in acute leukemia (3 of 35, 8.6%). 14-3-3σ protein was readily detectable and roughly reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3σ gene was not associated with expression in hematological malignancies. Mutations of p53 were identified in 12 patients and associated with lower expression of 14-3-3σ. The expression levels of 14-3-3σ, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth. CONCLUSION: 14-3-3σ, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies. This is the first report of aberrant 14-3-3σ expression in non-epithelial tumors in vivo. Since the significance of 14-3-3σ overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3σ gene in non-epithelial as well as epithelial tumors is warranted. |
format | Text |
id | pubmed-2222637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22226372008-02-01 Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies Motokura, Toru Nakamura, Yukari Sato, Hiroyuki BMC Cancer Research Article BACKGROUND: 14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ expression in patients with haematological malignancies. METHODS: We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3σ expression with real-time RT-PCR. We also examined protein levels by Western blot analysis and DNA methylation status of the 14-3-3σ gene by methylation-specific PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-PCR-SSCP analysis and the expression levels of 14-3-3σ were compared with those of other cell-cycle inhibitor genes, CDKN2A and ARF. RESULTS: The expression levels of 14-3-3σ mRNA in almost all cell lines were low and comparable to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3σ mRNA was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and rarely in acute leukemia (3 of 35, 8.6%). 14-3-3σ protein was readily detectable and roughly reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3σ gene was not associated with expression in hematological malignancies. Mutations of p53 were identified in 12 patients and associated with lower expression of 14-3-3σ. The expression levels of 14-3-3σ, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth. CONCLUSION: 14-3-3σ, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies. This is the first report of aberrant 14-3-3σ expression in non-epithelial tumors in vivo. Since the significance of 14-3-3σ overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3σ gene in non-epithelial as well as epithelial tumors is warranted. BioMed Central 2007-11-25 /pmc/articles/PMC2222637/ /pubmed/18036248 http://dx.doi.org/10.1186/1471-2407-7-217 Text en Copyright © 2007 Motokura et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Motokura, Toru Nakamura, Yukari Sato, Hiroyuki Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies |
title | Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies |
title_full | Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies |
title_fullStr | Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies |
title_full_unstemmed | Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies |
title_short | Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies |
title_sort | aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222637/ https://www.ncbi.nlm.nih.gov/pubmed/18036248 http://dx.doi.org/10.1186/1471-2407-7-217 |
work_keys_str_mv | AT motokuratoru aberrantoverexpressionofanepithelialmarker1433sinasubsetofhematologicalmalignancies AT nakamurayukari aberrantoverexpressionofanepithelialmarker1433sinasubsetofhematologicalmalignancies AT satohiroyuki aberrantoverexpressionofanepithelialmarker1433sinasubsetofhematologicalmalignancies |